Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза

1. Авезов С. А., Мансуров Ф. Х. Эффективность совместного применения урсодезоксихолевой кислоты и гептрала в лечении первичного билиарного цирроза. Клин мед 2004; 3:55-8.

2. Болезни печени и желчевыводящих путей. Руководство для врачей / Под ред. В. Т. Ивашкина. 2-е изд. М.: Изд. Дом «М-Вести», 2005:536 с.

3. Ивашкин В. Т., Буеверов А. О. Аутоиммунные заболевания печени в практике клинициста. 2-е изд. М.: Изд. Дом «М-Вести», 2011:112 с.

4. Ивашкин В. Т., Широкова Е. Н. Холестаз. Руководство для врачей. М.: СИМК, 2012:176 с.

5. Ивашкин В. Т., Широкова Е. Н., Маевская М. В., Ешану В. С., Павлов Ч. С., Золотаревский В. Б. Клиника и лечение аутоиммунного перекреста — аутоиммунного гепатита и первичного билиарного цирроза. Рос журн гастроэнтерол гепатол колопроктол 2005; 15(5):35-40.

6. Лейшнер У. Аутоиммунные заболевания печени и перекрестный синдром. М.: Анахарсис, 2005:174 с.

7. Рациональная фармакотерапия в гепатологии / Под ред. В. Т. Ивашкина, А. О. Буеверова. М.: Литтерра, 2009:296 с.

8. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Практич. руководство: Пер. с англ. / Под. ред. З. Г. Апросиной, Н. А. Мухина. М.: Гэотар Медицина, 1999:864 с.

9. Широкова Е. Н. Современные подходы к диагностике и лечению холестаза. Клин персп гастроэнтерол гепатол 2008; 4:33-9.

10. Широкова Е. Н. Молекулярные механизмы холестаза. Рос мед вести 2009; 1:15-22.

11. Широкова Е. Н., Ивашкин К. В., Ивашкин В. Т. Аутоиммунный гепатит: новое в диагностике, патогенезе и лечении. Рос журн гастроэнтерол гепатол колопроктол 2012; 22(5):37-45.

12. Широкова Е. Н., Кузнецова Е. Л., Маевская М. В., Павлов Ч. С., Золотаревский В. Б., Ивашкин В. Т. Эффективность урсодезоксихолевой кислоты в лечении больных холестатической формой алкогольной болезни печени и первичным билиарным циррозом. Рос журн гастроэнтерол гепатол колопроктол 2007; 17(3):52-8.

13. Alvarez F., Berg P. A., Bianchi F. B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31:929.

14. Baragiotta A., James O. F.W., Craig W., et al. Autoimmune hepatitis: clinical spectrum of disease defined by revised International Autoimmune Hepatitis Group (IAHG) scoring system. J Hepatol 2002; 35(Suppl. 1):261.

15. Beuers U. Hepatic overlap syndromes. J Hepatol 2005; 42(Suppl. 1):93-100.

16. Beuers U. Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3(6):318-28.

17. Binder T., Salaj P., Zima T., Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and Ы-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinatal Med 2006; 34:383-91.

18. Chan C. W., Gunsar F., Feudjo M., et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005; 21(3):217-26.

19. Chazouilleres O., Wendum D., Serfaty L., et al. Long term outcome and response to therapy of primary biliary cirrhosis — autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44(2):400-6.

20. Combes B., Luketic V. A., Peters M. G. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004; 99(2):264-8.

21. Corpechot C., Carrat F., Bonnand A. M., et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32(6):1196-9.

22. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128(2):297-303.

23. Czaja A. J. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34(10):659-65.

24. Czaja A. J. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A foray across diagnostic boundaries. J Hepatol 2006; 44:251-2.

25. Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30:134-46.

26. Dickson E. R., Grambsch P. M., Fleming T. R., et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10(1):1-7.

27. Durazzo M., Premoli A., Fagoonee S., Pelicano R. Overlap syndromes of autoimmune hepatitis: what as know so far. Dig Dis Sci 2003; 48(3):423-30.

28. Eriksson L. S., Olsson R., Glauman H., et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis: a Swedish multicenter, double-blind, randomized controlled study. Scand J Gastroenterol 1997; 32(2):179-86.

29. Gluud C., Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. The Cochrane database of systematic reviews 2001. Issue 4. Art.No.: CD000551. DOI:10.1002/14651858.CD000551.

30. Gong Y., Huang Z., Christensen E., Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102:1799-807.

31. Goulis J., Leandro G., Burroughs A. K. Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354(9184):1053-60.

32. Gunsar F., Akara U. S., Ersoz G., et al. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepato-Gastroenterol 2002; 49:1195-2000.

33. Heathcote E. J. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evalution of a modified scoring system. Am J Gastroenterol 2002; 97(5):1090-2.

34. Heathcote J. Diagnosis of primary biliary liver diseases, overlap syndromes and changing diagnosis. In: Dienes H.-P., Leuschner U., Lohse A. W., Manns M. P., eds. Autoimmune liver diseases. Dordrecht: Springer; 2005:171-9.

35. Jones D. E. Pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2008; 12 (2):305-21.

36. Kaplan M. M., Gershwin M. E. Primary biliary cirrhosis. N Engl J Med 2005; 353(12):1261-73.

37. Keitel V., Burdelski M., Warskulat U., et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005; 42(4):977-8.

38. Kis J., Csepregi A., Strassburg C. P., et al. Antimitochondrial antibodies against dihydrolipoamide acyltransferases (PDC-E2 and BCKADCE2) in immunofluorescent AMA-negative rheumatoid arthritis sera. J Hepatol 2002; 36(Suppl. 1):153.

39. Konstantinos N. L., Gores G. J., Lindor K. D. Ursodeoxycholic acid «mechanims of action and clinical use in hepatobiliary disorders». J Hepatol 2001; 35:134-46.

40. Kosters A., Karpen S. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis 2010; 30:186-94.

41. Kuntz E., Kuntz H. Hepatology principles and practice, 2nd ed. Springer Verlag Berlin, Heiderberg, 2006:906 p.

42. Lam P., Soroka C., Boyer J. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis 2010; 30:125-33.

43. Lazaridis K. N., Gores G. J., Lindor K. D. Ursodeoxycholic acid «mechanisms of action and clinical use in hepatobiliary disorders». J Hepatol 2001; 35:134-46.

44. Leuschner U., Manns M. P., Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis. Z Gastroenterol 2005; 43:1051-9.

45. Lindor K. D., Poupon R., Poupon R., et al. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000; 355(9204):657-8.

46. Lindor K. D., Talwalkar J. A., eds. Cholestatic liver disease. New Jersey: Humana Press, 2008:188 p.

47. Marschall H. U., Wagner M., Zollner G., Fickert P., et al. Rifampicin and ursodeoxycholic acid in cholestatic liver disease. Gastroenterology 2005; 129(2):476-85.

48. Noe J., Kullak-Ublick G.A., Jochum W., Stieger B., et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol 2005; 43(3):536-43.

49. Papatheodoridis G. V., Deutsch M., Hadziyannis E., et al. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year prspective rendomised controlled trial. J Hepatol 2000; 32(Suppl. 2):40A.

50. Pares A., Caballeria L., Rodes J., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32:561-6.

51. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with in primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-20.

52. Paulusma C., Ronald P., Elferink O., Jansen P. Progressive familial intrahepatic cholestasis type 1. Semin Liver Dis 2010; 30:117-24.

53. Paumgartner G., Pusl T. Medical treatment of cholestatic liver disease. Clin Liver Dis 2008; 12:53-81.

54. Poupon R. E. Management of primary biliary cirrhosis resistant to UDCA therapy. J Hepatol 2000; 32 (Suppl. 2):19-20.

55. Poupon R. E., Bonnard A. M., Chretien Y., et al. Tenyear survival in ursodeoxycholic acid treated patients with primary biliary cirrhosis. J Hepatol 1999; 29:1668-71.

56. Poupon R. E., Chazouilleres O., Poupon R. Chronic сholestatic diseases. J. Hepatol 2000; 32 (Suppl 1):129-40.

57. Poupon R.E, Lindor K. D., Pares A. M., et al. Combined analysis of the effect of treatmet with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39(1):12-6.

58. Roda E., Azzaroli F., Nigro G., Piazza F., Jaboli F., Ferrara F., et al. Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis 2002; 34:523-7.

59. Roncaglia N., et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111(1):17-21.

60. Selmi C., Zuin M., Bowlus C. L., Gershwin M. E. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis 2008; 12:173-87.

61. Silveira M. G., Talwalkar J. A., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long term outcomes. Am J Gastroenterol 2007; 102(6):1244-50.

62. Suzuki H., Sugiyama Y. Transport of drugs across the hepatic sinusoidal membrane: Sinusoidal drug influx and efflux in the liver. Semin Liver Dis 2000; 20:251-63.

63. Talwalkar J. A., Keach J. C., Angulo P., Lindor K. D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evalution of a modified scoring system. Am J Gastroenterol 2001; 97(5):1191-7.

64. Ter Borg P. C., Schalm S. W., Hansen B. E., et al. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101(9):2044-50.

65. Trauner M., Wagner M., Fickert P., Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 2005; 39(4):111-24.

66. Vergany D., Mieli-Vergani G. Autoimmune hepatitis and PSC connection. Clin Liver Dis 2008; 12:187-203.

67. Vierling J. M. Future treatment options in PBC. Semin Liver Dis 2005; 25(3):347-63.

68. Zollner G., Trauner M. Mechanisms of cholestasis. Clin Liver Dis 2008; 12(1):1-26.